PCSK9 and familial hypercholesterolemia: Marketed PCSK9 mAb inhibitors evolocumab and alirocumab are currently being used for the treatment of homozygous familial hypercholesterolemia proving the therapeutic potential of targeting PCSK9 [24,25,26].